EA201990052A1 - ПОЛУЧЕНИЕ ПРОИЗВОДНЫХ ФАКТОРА Ха - Google Patents

ПОЛУЧЕНИЕ ПРОИЗВОДНЫХ ФАКТОРА Ха

Info

Publication number
EA201990052A1
EA201990052A1 EA201990052A EA201990052A EA201990052A1 EA 201990052 A1 EA201990052 A1 EA 201990052A1 EA 201990052 A EA201990052 A EA 201990052A EA 201990052 A EA201990052 A EA 201990052A EA 201990052 A1 EA201990052 A1 EA 201990052A1
Authority
EA
Eurasian Patent Office
Prior art keywords
protein
chromatograph
obtaining derivative
derivative factors
factors
Prior art date
Application number
EA201990052A
Other languages
English (en)
Other versions
EA037815B1 (ru
Inventor
Марк Карбарз
Памела Б. Конли
Гэньминь Лу
Original Assignee
Портола Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60663351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201990052(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Портола Фармасьютикалз, Инк. filed Critical Портола Фармасьютикалз, Инк.
Publication of EA201990052A1 publication Critical patent/EA201990052A1/ru
Publication of EA037815B1 publication Critical patent/EA037815B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Настоящее изобретение предлагает способы крупномасштабного производства производного белка fXa, которые приводят к высокому выходу высокочистого белкового продукта. Способ может включать добавление детергента к образцу, который содержит полинуклеотидную конструкцию, кодирующую белок, и очистку белка с помощью хроматографа для афинной хроматографии на основе ингибитора трипсина сои (STI), хроматографа с ионным обменом и смешанным режимом и хроматографа с гидрофобным взаимодействием.
EA201990052A 2016-06-17 2017-06-19 ПОЛУЧЕНИЕ ПРОИЗВОДНЫХ ФАКТОРА Xa EA037815B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662351841P 2016-06-17 2016-06-17
PCT/US2017/038169 WO2017219034A2 (en) 2016-06-17 2017-06-19 Preparation of factor xa derivatives

Publications (2)

Publication Number Publication Date
EA201990052A1 true EA201990052A1 (ru) 2019-05-31
EA037815B1 EA037815B1 (ru) 2021-05-25

Family

ID=60663351

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990052A EA037815B1 (ru) 2016-06-17 2017-06-19 ПОЛУЧЕНИЕ ПРОИЗВОДНЫХ ФАКТОРА Xa

Country Status (23)

Country Link
US (4) US10604748B2 (ru)
EP (2) EP3472314B1 (ru)
JP (3) JP6959268B2 (ru)
KR (1) KR102373215B1 (ru)
CN (2) CN116425860A (ru)
AU (2) AU2017283720B2 (ru)
BR (1) BR112018075964A2 (ru)
CA (1) CA3027457A1 (ru)
CL (2) CL2018003654A1 (ru)
CO (1) CO2019000120A2 (ru)
DK (1) DK3472314T3 (ru)
EA (1) EA037815B1 (ru)
ES (1) ES2875538T3 (ru)
HU (1) HUE054597T2 (ru)
IL (1) IL263591B2 (ru)
MX (1) MX2018015873A (ru)
PE (1) PE20190661A1 (ru)
PH (1) PH12018502614A1 (ru)
PL (1) PL3472314T3 (ru)
PT (1) PT3472314T (ru)
SG (1) SG11201810915QA (ru)
SI (1) SI3472314T1 (ru)
WO (1) WO2017219034A2 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2414517B1 (en) * 2009-03-30 2016-09-21 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
SG10201705189XA (en) * 2013-01-24 2017-07-28 Portola Pharm Inc INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES
AU2017283720B2 (en) * 2016-06-17 2022-11-17 Alexion Pharmaceuticals, Inc. Preparation of factor Xa derivatives
EP3810187A4 (en) * 2018-06-19 2022-08-31 Alexion Pharmaceuticals, Inc. ANTIDOTES FOR FACTOR XA INHIBITORS
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189019A (en) 1990-04-23 1993-02-23 Merck & Co., Inc. Antistasin derived anticoagulant protein
US5589571A (en) * 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
JPH1066572A (ja) * 1996-08-29 1998-03-10 Showa Sangyo Co Ltd 高純度の大豆トリプシンインヒビターの製造方法
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
ATE549317T1 (de) 2005-11-08 2012-03-15 Millennium Pharm Inc Pharmazeutische salze und polymorphe aus n-(5- chloro-2-pyridinyl)-2-ää4- ä(dimethylamino)iminomethylübenzoylüaminoü-5- methoxy-benzamid, einem faktor-xa-hemmer
BRPI0816837B1 (pt) 2007-09-28 2022-10-18 Portola Pharmaceuticals, Inc Composições farmacêuticas, polipeptídeo isolado de duas cadeias e uso de uma composição farmacêutica
KR101649770B1 (ko) 2008-11-14 2016-08-19 포톨라 파마슈티컬스, 인코포레이티드 인자 ｘａ 저해제에 대한 해독제 및 혈액 응고제와 조합된 그의 사용 방법
EP2414517B1 (en) 2009-03-30 2016-09-21 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
US9056106B2 (en) 2009-07-15 2015-06-16 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same
KR102210574B1 (ko) * 2012-06-14 2021-02-01 포톨라 파마슈티컬스, 인코포레이티드 재조합 인자 Xa 유도체의 정제방법
US20140346397A1 (en) * 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
SG10201705189XA (en) 2013-01-24 2017-07-28 Portola Pharm Inc INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES
AU2014326257B2 (en) * 2013-09-24 2017-08-10 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins
CN107073082B (zh) * 2014-08-20 2021-04-30 博尔托拉制药公司 Xa因子解毒剂的冻干制剂
AU2017283720B2 (en) * 2016-06-17 2022-11-17 Alexion Pharmaceuticals, Inc. Preparation of factor Xa derivatives

Also Published As

Publication number Publication date
CN110167575B (zh) 2024-03-15
US20210348149A1 (en) 2021-11-11
AU2017283720A1 (en) 2019-01-03
HUE054597T2 (hu) 2021-09-28
DK3472314T3 (da) 2021-07-26
IL263591B (en) 2022-11-01
EP3472314A2 (en) 2019-04-24
IL263591A (en) 2019-02-03
AU2017283720B2 (en) 2022-11-17
CL2020001733A1 (es) 2020-09-25
US10604748B2 (en) 2020-03-31
JP2023086970A (ja) 2023-06-22
SI3472314T1 (sl) 2021-11-30
PE20190661A1 (es) 2019-05-08
CA3027457A1 (en) 2017-12-21
JP2019528242A (ja) 2019-10-10
JP6959268B2 (ja) 2021-11-02
AU2023200825A1 (en) 2023-03-16
KR20190019134A (ko) 2019-02-26
EP3472314B1 (en) 2021-05-05
JP2022000477A (ja) 2022-01-04
KR102373215B1 (ko) 2022-03-10
CL2018003654A1 (es) 2019-01-25
PH12018502614A1 (en) 2019-09-30
CN110167575A (zh) 2019-08-23
US20200208131A1 (en) 2020-07-02
US11845966B2 (en) 2023-12-19
EP3472314A4 (en) 2020-01-22
US20240076642A1 (en) 2024-03-07
JP7273918B2 (ja) 2023-05-15
ES2875538T3 (es) 2021-11-10
BR112018075964A2 (pt) 2019-04-02
IL263591B2 (en) 2023-03-01
US20170369862A1 (en) 2017-12-28
MX2018015873A (es) 2019-08-12
CO2019000120A2 (es) 2019-03-29
EA037815B1 (ru) 2021-05-25
CN116425860A (zh) 2023-07-14
EP3926044A1 (en) 2021-12-22
WO2017219034A2 (en) 2017-12-21
PL3472314T3 (pl) 2021-11-22
WO2017219034A3 (en) 2019-03-14
PT3472314T (pt) 2021-06-18
US10954504B2 (en) 2021-03-23
SG11201810915QA (en) 2019-01-30

Similar Documents

Publication Publication Date Title
EA201990052A1 (ru) ПОЛУЧЕНИЕ ПРОИЗВОДНЫХ ФАКТОРА Ха
IN2013MU02145A (ru)
MX2018002831A (es) Polipeptidos.
EA201792012A1 (ru) Использование щелочных промывочных растворов во время хроматографии для удаления примесей
WO2015195453A3 (en) Methods for increasing the capacity of flow-through processes
MX2016011641A (es) Procedimiento de preparacion de proteinas plasmaticas humanas.
MX2020000288A (es) Cromatografia.
MX364908B (es) Purificación de proteínas usando amortiguador bis-tris.
CY1121519T1 (el) Καθαρισμος της υδουρονικης-2-σουλφατασης
EA201891878A1 (ru) Очистка белков
MX368142B (es) Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.
EA201892624A1 (ru) Растения, дающие бессемянные плоды
MX2018015654A (es) Cromatografía de interacción hidrofóbica para la purificación de oligonucleótidos.
MX2016017115A (es) Metodos y reactivos para la purificacion de proteinas.
MX2023008870A (es) Composiciones y metodos para reducir la carga biologica en cromatografia.
EA201790250A1 (ru) Способ выделения полиовируса из культур клеток
MX2016013416A (es) Nuevo proceso de purificacion de gonadotropina.
EA201792366A1 (ru) Способ разделения белка и прочих примесей и капсульных полисахаридов микроорганизмов
TR201818966T4 (tr) İyon değişim kromatografisi girdi optimizasyonunun açıklaması.
MX361536B (es) Proceso de sintesis de ambrox a partir de ageratina jocotepecana.
MY184085A (en) Method of protein manufacture
WO2016084100A3 (en) Novel and efficient method for large scale synthesis of romidepsin
CO2017007441A2 (es) Proceso para la purificación de ga-68 a partir del eluato que se deriva de generadores de 68ge/ 68ga y columnas cromatográficas para usarse en dicho proceso
EA201691510A1 (ru) Новые способы разделения горохового белка
WO2015004686A3 (en) A process for purification of efavirenz and intermediates thereof using chromatographic methods

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM